03/06/20 -"FY19/20 reported EPS was impacted by higher than expected financial expenses (due to increased interest expenses from new funding and interest on lease liabilities under IFRS 16) and tax charges ..."
Pages
64
Language
English
Published on
03/06/20
You may also be interested by these reports :
16/04/24
Drägerwerk reported softer-than-expected Q1 24 numbers, with sales declining by 2.6%. As expected, growth in the safety segment partly offset the ...
15/04/24
The FY23 reported EPS came in ahead of our expectations, as the firm more than offset the H2 23 wage inflation with very strong profit margin ...
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
09/04/24
bioMerieux has reported better-than-expected Q1 organic sales growth, with healthy growth visible across both segments. Besides this, a promising ...